SalubrisBio’s JK06 shows early promise, but can 5T4 ADCs move beyond niche excitement?
Find out how SalubrisBio’s JK06 data could reshape 5T4-targeted ADC development in lung and breast cancer.
Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors
Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.